|  | Conditions Treatments | Medical Conditions

FDA Recall of Azacitidine

Azacitidine, which is also sold under the brand name of Vidaza, is used primarily to treat myelodysplastic syndromes (MDS), a group of conditions affecting the blood and bone marrow which lead to the production of abnormal blood cells. Azacitidine is administered through injection.

  1. FDA Status

    • Azacitidine was approved by the FDA on May 19, 2004. There has never been a recall of azacitidine.

    Side Effects

    • Common side effects of azacitidine include nausea and anemia (a decrease in red blood cells or in hemoglobin content), vomiting, fever, diarrhea, constipation, thrombocytopenia (low number of platelets in blood), or neutropenia (reduction in neutrophils, a type of white blood cell).

    Interactions

    • Women should not become pregnant or breastfeed while on azacitidine. Men should not conceive children while on azacitidine. Do not receive any vaccinations or take any new medicines or supplements without first consulting your doctor, as azacitidine can change the way your body reacts to these.

Medical Conditions - Related Articles